Roche has inaugurated the Institute of Human Biology (IHB) in Basel as part of a 1.4 billion Swiss franc investment in its Swiss life sciences hub. The new institute will host up to 250 researchers and focus on developing advanced human model systems (organoids, organ-on-chip, AI-integrated approaches) to improve the predictability and efficiency of drug discovery.
Glimpse:
The IHB aims to overcome limitations of traditional animal and cell models by using human-based systems combined with artificial intelligence. It will support research in disease biology and help evaluate new treatments more accurately. The facility is expected to strengthen Roche’s translational bioengineering and computational biology capabilities.
Roche has officially opened its Institute of Human Biology (IHB) in Basel, Switzerland. The facility, located in Building 92, is a key part of Roche’s 1.4 billion Swiss franc investment in the Basel life sciences hub.
The institute will host up to 250 researchers and will focus on advancing human model systems such as organoids, microfluidic organ-on-chip technology, and AI-driven computational methods to better understand human disease biology and improve drug discovery outcomes.
Thomas Schinecker, CEO of Roche Group, highlighted the strategic importance of the institute: “By combining human organoid models with Artificial Intelligence, IHB has the potential to change how we discover and develop new medicines making research and development more predictive and more efficient.”
Azad Bonni, Global Head and Director of the Institute of Human Biology, added: “By pioneering human model systems and better understanding human disease, we will move beyond the limitations of traditional research to predict if and how new treatments will work in people.”
Roche invests approximately 3.5 billion Swiss francs annually in research and development in Switzerland. The new institute is expected to significantly strengthen the company’s capabilities in translational bioengineering and computational biology.
“By combining human organoid models with Artificial Intelligence, IHB has the potential to change how we discover and develop new medicines making research and development more predictive and more efficient.”
By
HB Team
Related News
